

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: <b>A61F 2/00</b>	<b>A1</b>	(11) International Publication Number: <b>WO 00/02500</b> (43) International Publication Date: 20 January 2000 (20.01.2000)
---	-----------	--

(21) International Application Number: PCT/US99/15737

(22) International Filing Date: 12 July 1999 (12.07.1999)

## (30) Priority Data:

09/114,510 13 July 1998 (13.07.1998) US

09/114,757 13 July 1998 (13.07.1998) US

## (60) Parent Application or Grant

ACORN CARDIOVASCULAR, INC. [/]; (). ALFERNESSE,  
Clifton, A. [/]; (). RAMAN, Jai, S. [/]; (). POWER, John, M.  
[/]; (). SABBAH, Hani, N. [/]; (). DAIGNAULT, Ronald, A. ;  
().

**Published**(54) Title: **CARDIAC DISEASE TREATMENT DEVICE AND METHOD**(54) Titre: **DISPOSITIF ET PROCEDE DE TRAITEMENT DES MALADIES CARDIAQUES**

## (57) Abstract

A jacket of biological compatible material has an internal volume dimensioned for an apex of the heart to be inserted into the volume and for the jacket to be slipped over the heart. The jacket has a longitudinal dimension between upper and lower ends sufficient for the jacket to surround a lower portion of the heart with the jacket surrounding a valvular annulus of the heart and further surrounding the lower portion to cover at least the ventricular lower extremities of the heart. The jacket is adapted to be secured to the heart with the jacket surrounding at least the valvular annulus and the ventricular lower extremities. The jacket is adjustable on the heart to snugly conform to an external geometry of the heart and assume a maximum adjusted volume for the jacket to constrain circumferential expansion of the heart beyond the maximum adjusted volume during diastole and to permit unimpeded contraction of the heart during systole.

## (57) Abrégé

Une enveloppe en matériau biocompatible présente un volume intérieur dimensionné pour qu'un apex du coeur puisse être introduit à l'intérieur du volume et que l'enveloppe puisse être glissée sur le coeur. L'enveloppe présente une dimension longitudinale entre ses extrémités supérieure et inférieure qui est suffisante pour que l'enveloppe entoure une partie inférieure du coeur, un anneau valvulaire du coeur ainsi qu'une partie inférieure afin de recouvrir au moins les extrémités inférieures ventriculaires du coeur. L'enveloppe est adaptée pour être fixée sur le coeur de manière à entourer au moins l'anneau valvulaire et les extrémités inférieures ventriculaires. L'enveloppe est ajustable sur le coeur pour épouser les contours de la géométrie extérieure du coeur et assurer un volume ajusté maximum pour que l'enveloppe limite l'expansion circonférentielle du coeur au delà du volume ajusté maximum pendant la diastole et pour permettre la contraction non entravée du coeur pendant la systole.

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : A61F 2/00		A1	(11) International Publication Number: <b>WO 00/02500</b>
			(43) International Publication Date: 20 January 2000 (20.01.00)
(21) International Application Number: PCT/US99/15737			(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 12 July 1999 (12.07.99)			
(30) Priority Data: 09/114,510 13 July 1998 (13.07.98) US 09/114,757 13 July 1998 (13.07.98) US			
(71) Applicant: ACORN CARDIOVASCULAR, INC. [US/US]; 601 Campus Drive, St. Paul, MN 55112 (US).			
(72) Inventors: ALFERNESS, Clifton, A.; 9010 258th Avenue NE, Redmond, WA 98053 (US). RAMAN, Jai, S.; 30 The Boulevard, North Baldwyn, VIC 3104 (AU). POWER, John, M.; 65 Hannan Street, Williamstown, VIC 3016 (AU). SABBAH, Hani, N.; 1141 Meadowood, Waterford, WA 48327 (US).			
(74) Agent: DAIGNAULT, Ronald, A.; Merchant & Gould P.C., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402-4131 (US).			Published With international search report.

(54) Title: CARDIAC DISEASE TREATMENT DEVICE AND METHOD



(57) Abstract

A jacket of biological compatible material has an internal volume dimensioned for an apex of the heart to be inserted into the volume and for the jacket to be slipped over the heart. The jacket has a longitudinal dimension between upper and lower ends sufficient for the jacket to surround a lower portion of the heart with the jacket surrounding a valvular annulus of the heart and further surrounding the lower portion to cover at least the ventricular lower extremities of the heart. The jacket is adapted to be secured to the heart with the jacket surrounding at least the valvular annulus and the ventricular lower extremities. The jacket is adjustable on the heart to snugly conform to an external geometry of the heart and assume a maximum adjusted volume for the jacket to constrain circumferential expansion of the heart beyond the maximum adjusted volume during diastole and to permit unimpeded contraction of the heart during systole.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GK	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Description

5

10

15

20

25

30

35

40

45

50

55

**CARDIAC DISEASE TREATMENT DEVICE AND METHOD****I.****BACKGROUND OF THE INVENTION****1. Field of the Invention**

The present invention pertains to a device and method for treating heart disease. More particularly, the present invention is directed to a method and device for treating congestive heart disease and related valvular dysfunction.

**2. Description of the Prior Art**

Congestive heart disease is a progressive and debilitating illness. The disease is characterized by a progressive enlargement of the heart.

As the heart enlarges, the heart is performing an increasing amount of work in order to pump blood each heart beat. In time, the heart becomes so enlarged the heart cannot adequately supply blood. An afflicted patient is fatigued, unable to perform even simple exerting tasks and experiences pain and discomfort. Further, as the heart enlarges, the internal heart valves cannot adequately close. This impairs the function of the valves and further reduces the heart's ability to supply blood.

Causes of congestive heart disease are not fully known. In certain instances, congestive heart disease may result from viral infections. In such cases, the heart may enlarge to such an extent that the adverse consequences of heart enlargement continue after the viral infection has passed and the disease continues its progressively debilitating course.

Patients suffering from congestive heart disease are commonly grouped into four classes (i.e., Classes I, II, III and IV). In the early stages (e.g., Classes I and II), drug therapy is the commonly proscribed treatment. Drug therapy treats the symptoms of the disease and may slow the progression of the disease. Importantly, there is no cure for congestive heart disease. Even with drug therapy, the disease will progress. Further, the drugs may have adverse side effects.

5 Presently, the only permanent treatment for congestive heart disease is heart  
transplant. To qualify, a patient must be in the later stage of the disease (e.g.,  
Classes III and IV with Class IV patients given priority for transplant). Such  
patients are extremely sick individuals. Class III patients have marked physical  
10 activity limitations and Class IV patients are symptomatic even at rest.

Due to the absence of effective intermediate treatment between drug therapy  
and heart transplant, Class III and IV patients will have suffered terribly before  
15 qualifying for heart transplant. Further, after such suffering, the available treatment  
is unsatisfactory. Heart transplant procedures are very risky, extremely invasive and  
20 expensive and only shortly extend a patient's life. For example, prior to transplant, a  
Class IV patient may have a life expectancy of 6 months to one-year. Heart  
transplant may improve the expectancy to about five years.

Unfortunately, not enough hearts are available for transplant to meet the  
needs of congestive heart disease patients. In the United States, in excess of 35,000  
25 transplant candidates compete for only about 2,000 transplants per year. A  
transplant waiting list is about 8 – 12 months long on average and frequently a  
patient may have to wait about 1 – 2 years for a donor heart. While the availability  
30 of donor hearts has historically increased, the rate of increase is slowing  
dramatically. Even if the risks and expense of heart transplant could be tolerated,  
20 this treatment option is becoming increasingly unavailable. Further, many patient's  
do not qualify for heart transplant for failure to meet any one of a number of  
35 qualifying criteria.

Congestive heart failure has an enormous societal impact. In the United  
States alone, about five million people suffer from the disease (Classes I through IV  
40 combined). Alarming, congestive heart failure is one of the most rapidly  
accelerating diseases (about 400,000 new patients in the United States each year).  
Economic costs of the disease have been estimated at \$38 billion annually.

Not surprising, substantial effort has been made to find alternative treatments  
45 for congestive heart disease. Recently, a new surgical procedure has been  
developed. Referred to as the Batista procedure, the surgical technique includes  
30 dissecting and removing portions of the heart in order to reduce heart volume. This  
is a radical new and experimental procedure subject to substantial controversy.

5 Furthermore, the procedure is highly invasive, risky and expensive and commonly  
includes other expensive procedures (such as a concurrent heart valve replacement).  
Also, the treatment is limited to Class IV patients and, accordingly, provides no  
10 hope to patients facing ineffective drug treatment prior to Class IV. Finally, if the  
5 procedure fails, emergency heart transplant is the only available option.

Clearly, there is a need for alternative treatments applicable to both early and  
later stages of the disease to either stop the progressive nature of the disease or more  
15 drastically slow the progressive nature of congestive heart disease. Unfortunately,  
currently developed options are experimental, costly and problematic.

10 Cardiomyoplasty is a recently developed treatment for earlier stage  
congestive heart disease (e.g., as early as Class III dilated cardiomyopathy). In this  
20 procedure, the latissimus dorsi muscle (taken from the patient's shoulder) is wrapped  
around the heart and chronically paced synchronously with ventricular systole.  
Pacing of the muscle results in muscle contraction to assist the contraction of the  
25 heart during systole.

While cardiomyoplasty has resulted in symptomatic improvement, the nature  
of the improvement is not understood. For example, one study has suggested the  
30 benefits of cardiomyoplasty are derived less from active systolic assist than from  
remodeling, perhaps because of an external elastic constraint. The study suggests an  
20 elastic constraint (i.e., a non-stimulated muscle wrap or an artificial elastic sock  
placed around the heart) could provide similar benefits. Kass et al., *Reverse  
35 Remodeling From Cardiomyoplasty In Human Heart Failure: External Constraint  
Versus Active Assist*, 91 Circulation 2314 – 2318 (1995).

Even though cardiomyoplasty has demonstrated symptomatic improvement,  
40 25 studies suggest the procedure only minimally improves cardiac performance. The  
procedure is highly invasive requiring harvesting a patient's muscle and an open  
chest approach (i.e., sternotomy) to access the heart. Furthermore, the procedure is  
expensive -- especially those using a paced muscle. Such procedures require costly  
45 pacemakers. The cardiomyoplasty procedure is complicated. For example, it is  
30 difficult to adequately wrap the muscle around the heart with a satisfactory fit. Also,  
if adequate blood flow is not maintained to the wrapped muscle, the muscle may  
50 necrose. The muscle may stretch after wrapping reducing its constraining benefits



5 and is generally not susceptible to post-operative adjustment. Finally, the muscle  
may fibrose and adhere to the heart causing undesirable constraint on the contraction  
of the heart during systole.

10 In addition to cardiomyoplasty, mechanical assist devices have been  
5 developed as intermediate procedures for treating congestive heart disease. Such  
devices include left ventricular assist devices ("LVAD") and total artificial hearts  
("TAH"). An LVAD includes a mechanical pump for urging blood flow from the  
15 left ventricle and into the aorta. An example of such is shown in U.S. Patent No.  
4,995,857 to Arnold dated February 26, 1991. LVAD surgeries are still in U.S.  
20 clinical trials and not generally available. Such surgeries are expensive. The  
devices are at risk of mechanical failure and frequently require external power  
supplies. TAH devices, such as the celebrated Jarvik heart, are used as temporary  
measures while a patient awaits a donor heart for transplant.

25 Other attempts at cardiac assist devices are found in U.S. Patent No.  
4,957,477 to Lundbäck dated September 18, 1990, U.S. Patent No. 5,131,905 to  
Grooters dated July 21, 1992 and U.S. Patent No. 5,256,132 to Snyders dated  
October 26, 1993. Both of the Grooters and Snyders patents teach cardiac assist  
30 devices which pump fluid into chambers opposing the heart to assist systolic  
contractions of the heart. The Lundbäck patent teaches a double-walled jacket  
surrounding the heart. A fluid fills a chamber between the walls of the jacket. The  
20 inner wall is positioned against the heart and is pliable to move with the heart.  
Movement of the heart during beating displaces fluid within the jacket chamber.

35 Commonly assigned U.S. Patent No. 5,702,343 to Alferness dated December  
30, 1997 teaches a jacket to constrain cardiac expansion during diastole. The present  
25 invention pertains to improvements to the invention disclosed in the '343 patent.

## II.

### SUMMARY OF THE INVENTION

45 According to a preferred embodiment of the present invention, a method and  
device are disclosed for treating congestive heart disease and related cardiac  
30 complications such as valvular disorders. The invention includes a jacket of  
biologically compatible material. The jacket has an internal volume dimensioned for  
50 an apex of the heart to be inserted into the volume and for the jacket to be slipped

5 over the heart. The jacket has a longitudinal dimension between upper and lower  
ends sufficient for the jacket to surround a lower portion of the heart with the jacket  
surrounding a valvular annulus of the heart and further surrounding the lower  
10 portion to cover at least the ventricular lower extremities of the heart. The jacket is  
5 adapted to be secured to the heart with the jacket surrounding at least the valvular  
annulus and the ventricular lower extremities. The jacket is adjustable on the heart  
to snugly conform to an external geometry of the heart and assume a maximum  
15 adjusted volume for the jacket to constrain circumferential expansion of the heart  
beyond the maximum adjusted volume during diastole and to permit unimpeded  
10 contraction of the heart during systole. In one embodiment, a lower end of the jacket  
can be secured to the patient's diaphragm after placement around the heart.  
20

### III.

#### BRIEF DESCRIPTION OF THE DRAWINGS

25 Fig. 1 is a schematic cross-sectional view of a normal, healthy human heart  
15 shown during systole;

Fig. 1A is the view of Fig. 1 showing the heart during diastole;

Fig. 1B is a view of a left ventricle of a healthy heart as viewed from a  
30 septum and showing a mitral valve;

Fig. 2 is a schematic cross-sectional view of a diseased human heart shown  
20 during systole;

Fig. 2A is the view of Fig. 2 showing the heart during diastole;

35 Fig. 2B is the view of Fig. 1B showing a diseased heart;

Fig. 3 is a perspective view of a first embodiment of a cardiac constraint  
device according to the present invention;

40 25 Fig. 3A is a side elevation view of a diseased heart in diastole with the device  
of Fig. 3 in place;

Fig. 4 is a perspective view of a second embodiment of a cardiac constraint  
45 device according to the present invention;

Fig. 4A is a side elevation view of a diseased heart in diastole with the device  
30 of Fig. 4 in place;

Fig. 5 is a cross-sectional view of a device of the present invention overlying  
50 a myocardium and with the material of the device gathered for a snug fit;

Fig. 6 is an enlarged view of a knit construction of the device of the present invention in a rest state; and

Fig. 7 is a schematic view of the material of Fig. 6.

#### IV.

#### DESCRIPTION OF THE PREFERRED EMBODIMENT

With initial reference to Figs. 1 and 1A, a normal, healthy human heart H' is schematically shown in cross-section and will now be described in order to facilitate an understanding of the present invention. In Fig. 1, the heart H' is shown during systole (i.e., high left ventricular pressure). In Fig. 1A, the heart H' is shown during diastole (i.e., low left ventricular pressure).

The heart H' is a muscle having an outer wall or myocardium MYO' and an internal wall or septum S'. The myocardium MYO' and septum S' define four internal heart chambers including a right atrium RA', a left atrium LA', a right ventricle RV' and a left ventricle LV'. The heart H' has a length measured along a longitudinal axis AA' - BB' from an upper end or base B' to a lower end or apex A'.

The right and left atria RA', LA' reside in an upper portion UP' of the heart H' adjacent the base B'. The right and left ventricles RV', LV' reside in a lower portion LP' of the heart H' adjacent the apex A'. The ventricles RV', LV' terminate at ventricular lower extremities LE' adjacent the apex A' and spaced therefrom by the thickness of the myocardium MYO'.

Due to the compound curves of the upper and lower portions UP', LP', the upper and lower portions UP', LP' meet at a circumferential groove commonly referred to as the A-V groove AVG'. Extending away from the upper portion UP' are a plurality of major blood vessels communicating with the chambers RA', RV', LA', LV'. For ease of illustration, only the superior vena cava SVC' and a left pulmonary vein LPV' are shown as being representative.

The heart H' contains valves to regulate blood flow between the chambers RA', RV', LA', LV' and between the chambers and the major vessels (e.g., the superior vena cava SVC' and a left pulmonary vein LPV'). For ease of illustration, not all of such valves are shown. Instead, only the tricuspid valve TV' between the right atrium RA' and right ventricle RV' and the mitral valve MV' between the left atrium LA' and left ventricle LV' are shown as being representative.

5 The valves are secured, in part, to the myocardium MYO' in a region of the lower portion LP' adjacent the A-V groove AVG' and referred to as the valvular annulus VA'. The valves TV' and MV' open and close through the beating cycle of the heart H.

10 5 Figs. 1 and 1A show a normal, healthy heart H' during systole and diastole, respectively. During systole (Fig. 1), the myocardium MYO' is contracting and the heart assumes a shape including a generally conical lower portion LP'. During diastole (Fig. 1A), the heart H' is expanding and the conical shape of the lower portion LP' bulges radially outwardly (relative to axis AA' - BB').

15 10 The motion of the heart H' and the variation in the shape of the heart H' during contraction and expansion is complex. The amount of motion varies considerably throughout the heart H'. The motion includes a component which is parallel to the axis AA' - BB' (conveniently referred to as longitudinal expansion or contraction). The motion also includes a component perpendicular to the axis AA'-BB' (conveniently referred to as circumferential expansion or contraction).

20 15 Having described a healthy heart H' during systole (Fig. 1) and diastole (Fig. 1A), comparison can now be made with a heart deformed by congestive heart disease. Such a heart H is shown in systole in Fig. 2 and in diastole in Fig. 2A. All elements of diseased heart H are labeled identically with similar elements of healthy heart H' except only for the omission of the apostrophe in order to distinguish diseased heart H from healthy heart H'.

30 20 Comparing Figs. 1 and 2 (showing hearts H' and H during systole), the lower portion LP of the diseased heart H has lost the tapered conical shape of the lower portion LP' of the healthy heart H'. Instead, the lower portion LP of the diseased heart H bulges outwardly between the apex A and the A-V groove AVG. So deformed, the diseased heart H during systole (Fig. 2) resembles the healthy heart H' during diastole (Fig. 1A). During diastole (Fig. 2A), the deformation is even more extreme.

45 25 As a diseased heart H enlarges from the representation of Figs. 1 and 1A to that of Figs. 2 and 2A, the heart H becomes a progressively inefficient pump. Therefore, the heart H requires more energy to pump the same amount of blood. Continued progression of the disease results in the heart H being unable to supply

adequate blood to the patient's body and the patient becomes symptomatic insufficiency.

For ease of illustration, the progression of congestive heart disease has been illustrated and described with reference to a progressive enlargement of the lower portion LP of the heart H. While such enlargement of the lower portion LP is most common and troublesome, enlargement of the upper portion UP may also occur.

In addition to cardiac insufficiency, the enlargement of the heart H can lead to valvular disorders. As the circumference of the valvular annulus VA increases, the leaflets of the valves TV and MV may spread apart. After a certain amount of enlargement, the spreading may be so severe the leaflets cannot completely close (as illustrated by the mitral valve MV in Fig. 2A). Incomplete closure results in valvular regurgitation contributing to an additional degradation in cardiac performance. While circumferential enlargement of the valvular annulus VA may contribute to valvular dysfunction as described, the separation of the valve leaflets is most commonly attributed to deformation of the geometry of the heart H. This is best described with reference to Figs. 1B and 2B.

Figs. 1B and 2B show a healthy and diseased heart, respectively, left ventricle LV', LV during systole as viewed from the septum (not shown in Figs. 1B and 2B). In a healthy heart H', the leaflets MVL' of the mitral valve MV' are urged closed by left ventricular pressure. The papillary muscles PM', PM are connected to the heart wall MYO', MYO, near the lower ventricular extremities LE', LE. The papillary muscles PM', PM pull on the leaflets MVL', MVL via connecting chordae tendineae CT', CT. Pull of the leaflets by the papillary muscles functions to prevent valve leakage in the normal heart by holding the valve leaflets in a closed position during systole. In the significantly diseased heart H, the leaflets of the mitral valve may not close sufficiently to prevent regurgitation of blood from the ventricle LV to the atrium during systole.

As shown in Fig. 1B, the geometry of the healthy heart H' is such that the myocardium MYO', papillary muscles PM' and chordae tendineae CT' cooperate to permit the mitral valve MV' to fully close. However, when the myocardium MYO bulges outwardly in the diseased heart H (Fig. 2B), the bulging results in

5 displacement of the papillary muscles PM. This displacement acts to pull the leaflets MVL to a displaced position such that the mitral valve cannot fully close.

Having described the characteristics and problems of congestive heart disease, the treatment method and apparatus of the present invention will now be  
10 5 described.

In general, a jacket of the invention is configured to surround the myocardium MYO. As used herein, "surround" means that jacket provides reduced expansion of the heart wall during diastole by applying constraining surfaces at least  
15 at diametrically opposing aspects of the heart. In some preferred embodiments disclosed herein, the diametrically opposed surfaces are interconnected, for example,  
10 by a continuous material that can substantially encircle the external surface of the heart.  
20

With reference now to Figs. 3, 3A, 4 and 4A, the device of the present invention is shown as a jacket 10 of flexible, biologically compatible material. The  
25 15 jacket 10 is an enclosed knit material having upper and lower ends 12, 14. The jacket 10, 10' defines an internal volume 16, 16' which is completely enclosed but for the open ends 12, 12' and 14'. In the embodiment of Fig. 3, lower end 14 is closed. In the embodiment of Fig. 4, lower end 14' is open. In both embodiments,  
30 upper ends 12, 12' are open. Throughout this description, the embodiment of Fig. 3 will be discussed. Elements in common between the embodiments of Figs. 3 and 4 are numbered identically with the addition of an apostrophe to distinguish the second  
35 embodiment and such elements need not be separately discussed.

The jacket 10 is dimensioned with respect to a heart H to be treated. Specifically, the jacket 10 is sized for the heart H to be constrained within the  
40 25 volume 16. The jacket 10 can be slipped around the heart H. The jacket 10 has a length L between the upper and lower ends 12, 14 sufficient for the jacket 10 to constrain the lower portion LP. The upper end 12 of the jacket 10 extends at least to the valvular annulus VA and further extends to the lower portion LP to constrain at  
45 least the lower ventricular extremities LE.

30 Since enlargement of the lower portion LP is most troublesome, in a preferred embodiment, the jacket 10 is sized so that the upper end 12 can reside in  
50

5 the A-V groove AVG. Where it is desired to constrain enlargement of the upper portion UP, the jacket 10 may be extended to cover the upper portion UP.

10 Sizing the jacket 10 for the upper end 12 to terminate at the A-V groove AVG is desirable for a number of reasons. First, the groove AVG is a readily identifiable anatomical feature to assist a surgeon in placing the jacket 10. By placing the upper end 12 in the A-V groove AVG, the surgeon is assured the jacket 10 will provide sufficient constraint at the valvular annulus VA. The A-V groove AVG and the major vessels act as natural stops for placement of the jacket 10 while assuring coverage of the valvular annulus VA. Using such features as natural stops 15 is particularly beneficial in minimally invasive surgeries where a surgeon's vision may be obscured or limited.

20 When the parietal pericardium is opened, the lower portion LP is free of obstructions for applying the jacket 10 over the apex A. If, however, the parietal pericardium is intact, the diaphragmatic attachment to the parietal pericardium 25 inhibits application of the jacket over the apex A of the heart. In this situation, the jacket can be opened along a line extending from the upper end 12' to the lower end 14' of jacket 10'. The jacket can then be applied around the pericardial surface of the heart and the opposing edges of the opened line secured together after placed on the heart. Systems for securing the opposing edges are disclosed in, for example, U.S. 30 Patent No. 5,702,343, the entire disclosure of which is incorporated herein by reference. The lower end 14' can then be secured to the diaphragm or associated tissues using, for example, sutures, staples, etc.

35 In the embodiment of Figs. 3 and 3A, the lower end 14 is closed and the length L is sized for the apex A of the heart H to be received within the lower end 14 40 when the upper end 12 is placed at the A-V groove AVG. In the embodiment of Figs. 4 and 4A, the lower end 14' is open and the length L' is sized for the apex A of the heart H to protrude beyond the lower end 14' when the upper end 12' is placed at the A-V groove AVG. The length L' is sized so that the lower end 14' extends 45 beyond the lower ventricular extremities LE such that in both of jackets 10, 10', the myocardium MYO surrounding the ventricles RV, LV is in direct opposition to 30 material of the jacket 10, 10'. Such placement is desirable for the jacket 10, 10' to present a constraint against enlargement of the ventricular walls of the heart H.

5 After the jacket 10 is positioned on the heart H as described above, the jacket 10 is secured to the heart. Preferably, the jacket 10 is secured to the heart H through sutures. The jacket 10 is sutured to the heart H at suture locations S  
10 5 circumferentially spaced along the upper end 12. While a surgeon may elect to add additional suture locations to prevent shifting of the jacket 10 after placement, the number of such locations S is preferably limited so that the jacket 10 does not restrict contraction of the heart H during systole.

15 To permit the jacket 10 to be easily placed on the heart H, the volume and shape of the jacket 10 are larger than the lower portion LP during diastole. So sized,  
20 10 the jacket 10 may be easily slipped around the heart H. Once placed, the jacket's volume and shape are adjusted for the jacket 10 to snugly conform to the external geometry of the heart H during diastole. Such sizing is easily accomplished due to the knit construction of the jacket 10. For example, excess material of the jacket 10 can be gathered and sutured S" (Fig. 5) to reduce the volume of the jacket 10 and  
25 15 conform the jacket 10 to the shape of the heart H during diastole. Such shape represents a maximum adjusted volume. The jacket 10 constrains enlargement of the heart H beyond the maximum adjusted volume while preventing restricted contraction of the heart H during systole. As an alternative to gathering of Fig. 5,  
30 20 the jacket 10 can be provided with other ways of adjusting volume. For example, as disclosed in U.S. Patent No. 5,702,343, the jacket can be provided with a slot. The edges of the slot can be drawn together to reduce the volume of the jacket.

35 The jacket 10 is adjusted to a snug fit on the heart H during diastole. Care is taken to avoid tightening the jacket 10 too much such that cardiac function is impaired. During diastole, the left ventricle LV fills with blood. If the jacket 10 is  
40 25 too tight, the left ventricle LV cannot adequately expand and left ventricular pressure will rise. During the fitting of the jacket 10, the surgeon can monitor left ventricular pressure. For example, a well-known technique for monitoring so-called pulmonary wedge pressure uses a catheter placed in the pulmonary artery. The wedge pressure provides an indication of filling pressure in the left atrium LA and left ventricle LV.  
45 30 While minor increases in pressure (e.g., 2 – 3 mm Hg) can be tolerated, the jacket 10 is snugly fit on the heart H but not so tight as to cause a significant increase in left ventricular pressure during diastole.



5 As mentioned, the jacket 10 is constructed from a knit, biocompatible material. The knit 18 is illustrated in Fig. 6. Preferably, the knit is a so-called "Atlas knit" well known in the fabric industry. The Atlas knit is described in Paling, Warp Knitting Technology, p. 111, Columbine Press (Publishers) Ltd., Buxton, 10 Great Britain (1970).

The Atlas knit is a knit of fibers 20 having directional expansion properties. More specifically, the knit 18, although formed of generally inelastic fibers 20, 15 permits a construction of a flexible fabric at least slightly expandable beyond a rest state. Fig. 6 illustrates the knit 18 in a rest state. The fibers 20 of the fabric 18 are woven into two sets of fiber strands 21a, 21b having longitudinal axes  $X_a$  and  $X_b$ . 20 The strands 21a, 21b are interwoven to form the fabric 18 with strands 21a generally parallel and spaced-apart and with strands 21b generally parallel and spaced-apart.

For ease of illustration, fabric 18 is schematically shown in Fig. 7 with the axis of the strands 21a, 21b only being shown. The strands 21a, 21b are interwoven 25 with the axes  $X_a$  and  $X_b$  defining a diamond-shaped open cell 23 having diagonal axes  $A_m$ . In a preferred embodiment, the axes  $A_m$  are 5 mm in length when the fabric 18 is at rest and not stretched. The fabric 18 can stretch in response to a force. For 30 any given force, the fabric 18 stretches most when the force is applied parallel to the diagonal axes  $A_m$ . The fabric 18 stretches least when the force is applied parallel to the strand axes  $X_a$  and  $X_b$ . The jacket 10 is constructed for the material of the knit to be directionally aligned for a diagonal axis  $A_m$  to be parallel to the heart's 35 longitudinal axis AA-BB

While the jacket 10 is expandable due to the above described knit pattern, the fibers 20 of the knit 18 are preferably non-expandable. While all materials expand 40 to at least a small amount, the fibers 20 are preferably formed of a material with a low modulus of elasticity. In response to the low pressures in the heart H during diastole, the fibers 20 are non-elastic. In a preferred embodiment, the fibers are 70 Denier polyester. While polyester is presently preferred, other suitable materials include polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), polypropylene 45 and stainless steel. 30

The knit material has numerous advantages. Such a material is flexible to 50 permit unrestricted movement of the heart H (other than the desired constraint on

5 circumferential expansion). The material is open defining a plurality of interstitial spaces for fluid permeability as well as minimizing the amount of surface area of direct contact between the heart H and the material of the jacket 10 (thereby minimizing areas of irritation or abrasion) to minimize fibrosis and scar tissue.

10 5 The open areas of the knit construction also allows for electrical connection between the heart and surrounding tissue for passage of electrical current to and from the heart. For example, although the knit material is an electrical insulator, the open knit construction is sufficiently electrically permeable to permit the use of trans-chest defibrillation of the heart. Also, the open, flexible construction permits 15 passage of electrical elements (e.g., pacer leads) through the jacket. Additionally, the open construction permits other procedures, e.g., coronary bypass, to be performed without removal of the jacket. 20

A large open area for cells 23 is desirable to minimize the amount of surface area of the heart H in contact with the material of the jacket 10 (thereby reducing 25 fibrosis). However, if the cell area 23 is too large, localized aneurysm can form. Also, a strand 21a, 21b can overly a coronary vessel with sufficient force to partially block the vessel. A smaller cell size increases the number of strands thereby decreasing the restricting force per strand. Preferably, a maximum cell area is no greater than about 6.45 cm<sup>2</sup> (about 2.54 cm by 2.54 cm) and, more preferably, is 30 about .25 cm<sup>2</sup> (about .5 cm by .5 cm). The maximum cell area is the area of a cell 23 after the material of the jacket 10 is fully stretched and adjusted to the maximum adjusted volume on the heart H as previously described. 35

The fabric 18 is preferably tear and run resistant. In the event of a material defect or inadvertent tear, such a defect or tear is restricted from propagation by 40 25 reason of the knit construction.

With the foregoing, a device and method have been taught to treat cardiac disease. The jacket 10 constrains further undesirable circumferential enlargement of the heart while not impeding other motion of the heart H. With the benefits of the 45 present teachings, numerous modifications are possible. For example, the jacket 10 need not be directly applied to the epicardium (i.e., outer surface of the myocardium) 30 but could be placed over the parietal pericardium. Further, an anti-fibrosis lining 50

5 (such as a PTFE coating on the fibers of the knit) could be placed between the heart H and the jacket 10. Alternatively, the fibers 20 can be coated with PTFE.

10 The jacket 10 is low-cost, easy to place and secure, and is susceptible to use in minimally invasive procedures. The thin, flexible fabric 18 permits the jacket 10 to be collapsed and passed through a small diameter tube in a minimally invasive procedure.

15 The jacket 10 can be used in early stages of congestive heart disease. For patients facing heart enlargement due to viral infection, the jacket 10 permits constraint of the heart H for a sufficient time to permit the viral infection to pass. In addition to preventing further heart enlargement, the jacket 10 treats valvular disorders by constraining circumferential enlargement of the valvular annulus and deformation of the ventricular walls.

20 The jacket 10, including the knit construction, freely permits longitudinal and circumferential contraction of the heart H (necessary for heart function). Unlike a solid wrap (such as a muscle wrap in a cardiomyoplasty procedure), the fabric 18 does not impede cardiac contraction. After fitting, the jacket 10 is inelastic to prevent further heart enlargement while permitting unrestricted inward movement of the ventricular walls. The open cell structure permits access to coronary vessels for bypass procedures subsequent to placement of the jacket 10. Also, in cardiomyoplasty, the latissimus dorsi muscle has a variable and large thickness (ranging from about 1 mm to 1 cm). The material of the jacket 10 is uniformly thin (less than 1 mm thick). The thin wall construction is less susceptible to fibrosis and minimizes interference with cardiac contractile function.

25 Animal test studies on the device show the efficacy of the invention. Test animals were provided with the device 10 of Fig. 3. The animals' hearts were rapidly paced to induce enlargement. After six weeks, animals without the device experienced significant heart enlargement while those with the device experienced no significant enlargement. Further, animals with the device had significantly reduced mitral valve regurgitation.

30 In addition to the foregoing, the present invention can be used to reduce heart size at the time of placement in addition to preventing further enlargement. For example, the device can be placed on the heart and sized snugly to urge the heart to a

5 reduced size. More preferably, the heart size can be reduced at the time of jacket  
placement through drugs (e.g., dobutamine, dopamine or epinephrine or any other  
positive inotropic agents) to reduce the heart size. The jacket of the present  
invention is then snugly placed on the reduced sized heart and prevents enlargement  
10 5 beyond the reduced size.

From the foregoing, a low cost, reduced risk method and device are taught to  
treat cardiac disease. The invention is adapted for use with both early and later stage  
15 congestive heart disease patients. The invention reduces the enlargement rate of the  
heart as well as reducing cardiac valve regurgitation.

10

20

25

30

35

40

45

50

55

**Claims**

5

10

15

20

25

30

35

40

45

50

55

What is claimed is:

1. A device for treating cardiac disease of a heart having a longitudinal axis from an apex to a base and having an upper portion and a lower portion divided by an A-V groove, said heart including a valvular annulus adjacent said A-V groove and ventricular lower extremities adjacent said apex, the device comprising:

- a jacket of flexible material of knit construction defining a volume between an open upper end and a lower end, said jacket dimensioned for said apex of said heart to be inserted into said volume through said open upper end and for said jacket to be slipped over said heart, said jacket further dimensioned for said jacket to have a longitudinal dimension between said upper and lower ends sufficient for said jacket to constrain said lower portion with said jacket constraining said valvular annulus and further constraining said ventricular lower extremities;

- said jacket adapted to be secured to said heart with said jacket having portions disposed on opposite sides of the heart between said valvular annulus and said ventricular lower extremities; and

- said jacket adapted to be adjusted on said heart to snugly conform to an external geometry of said heart and assume a maximum adjusted volume for said jacket to constrain circumferential expansion of said heart beyond said maximum adjusted volume during diastole and permit substantially unimpeded contraction of said heart during systole.

2. A device according to claim 2 wherein:

- said material is expandable along a first material axis in response to a force parallel to said first axis greater than an expansion of said material along a second axis in response to a force of equal magnitude parallel to said second axis;

5

15

10.

20

25

15

30

20

- said material oriented for said first axis to extend from said upper end of said jacket toward said lower end.

25    7.    A device according to claim 1 wherein said material is sufficiently flexible to  
gather excess amounts of said material following placement of said jacket  
over said heart to snugly conform said material to an external geometry of  
said heart.

45

30

50

5 over said heart to snugly conform said material to an external geometry of  
said heart.

10 9. A device according to claim 1 wherein said material is selected from a group  
5 of polytetrafluoroethylene, expanded polytetrafluoroethylene, polypropylene,  
polyester or stainless steel.

15 10. A device according to claim 5 wherein said material is formed of elongated  
fibers selected from a group of polytetrafluoroethylene, expanded  
10 polytetrafluoroethylene, polypropylene, polyester or stainless steel.

20 11. A device according to claim 1 wherein said jacket is sized to at least partially  
cover and constrain said upper portion.

25 12. A device according to claim 1 further comprising a liner sized and positioned  
15 to be disposed between said heart and said jacket, said liner formed of an  
anti-fibrotic material.

30 13. A device according to claim 1 wherein the jacket is electrically permeable.  
20

35 14. A device for treating cardiac disease of a heart having a longitudinal axis  
from an apex to a base and having an upper portion and a lower portion  
divided by an A-V groove, said heart including a valvular annulus adjacent  
said A-V groove and ventricular lower extremities adjacent said apex, the  
40 25 device comprising:

- 45 - a jacket of flexible, electrically permeable material adapted to be  
secured to said heart with said jacket having portions disposed on  
opposite sides of the heart between said valvular annulus and said  
30 ventricular lower extremities; and



5

- said jacket adapted to be adjusted on said heart to snugly conform to an external geometry of said heart and assume a maximum adjusted volume for said jacket to constrain circumferential expansion of said heart beyond said maximum adjusted volume during diastole and permit unimpeded contraction of said heart during systole.

10

5

15

15. A device according to claim 2 wherein said jacket circumferentially surrounds said heart.

20

- 10 16. A method for treating cardiac disease of a patient's heart, said method comprising:

25

15

- surgically accessing said patient's heart and diaphragm;
- placing a jacket around said heart, said jacket comprising a biomedical material having an upper end and a lower end;
- adjusting said jacket on said heart to snugly conform to an external geometry of said heart and assume a maximum adjusted volume for said jacket to constrain circumferential expansion of said heart beyond said maximum adjusted volume during diastole and permitting unimpeded contraction of said heart during systole; and
- securing said lower end of said jacket to said diaphragm.

30

20

35

40

25

17. A method according to claim 16 wherein said lower end of said jacket is secured to said diaphragm using sutures.

45

30

18. A method for treating cardiac disease of a heart having a longitudinal axis from an apex to a base and having an upper portion and a lower portion divided by an A-V groove, said heart including a valvular annulus adjacent

50

55

5                   said A-V groove and ventricular lower extremities adjacent said apex, the  
method comprising:

- 10                   5                   - surgically accessing said heart;
- 15                   - applying a drug therapy to the heart to reduce a size of the heart;
- 20                   - placing a jacket on said heart;
- 25                   10                   - securing said jacket to said heart with said jacket having portions  
disposed on opposite sides of the heart between said valvular annulus  
and said ventricular lower extremities;
- 30                   15                   - adjusting said jacket on said heart after the drug therapy to snugly  
conform the jacket to an external geometry of said heart and assume a  
maximum adjusted volume for said jacket to constrain  
circumferential expansion of said heart beyond said maximum  
adjusted volume during diastole and permit unimpeded contraction of  
said heart during systole;
- 35                   20                   - surgically closing access to said heart while leaving said jacket in  
place on said heart.

40                   25                   19. A method according to claim 18 further comprising placing said jacket over  
said upper portion and snugly securing said jacket to said upper portion.

45                   20. A method according to claim 18 wherein the drug therapy includes  
administering a positive inotropic agent to the patient.




FIG. 1A

FIG. I




FIG. 2A




FIG. 2




FIG. 2B






FIG. 1B






FIG. 4 A




FIG. 4




FIG. 7





FIG. 5



FIG. 6



# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 99/15737

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61F2/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 702 343 A (ALFERNESS) 30 December 1997 (1997-12-30) cited in the application column 3, line 6 - line 20 column 4, line 31 - line 51	14
A	---	1,3,13
P,X	WO 98 58598 A (HAINDL) 30 December 1998 (1998-12-30)  the whole document	1,2,4,5, 7-10, 12-15
A	US 4 428 375 A (ELLMAN) 31 January 1984 (1984-01-31) column 2, line 30 - column 3, line 28	1,14

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claims) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 October 1999

Date of mailing of the international search report

03/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nt,  
Fax: (+31-70) 340-3018

Authorized officer

Schönleben, J

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 15737

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 16-20  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT-Method for treatment of the human or animal body by surgery
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/US 99/15737

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5702343	A	30-12-1997	AU 4745097 A EP 0930856 A WO 9814136 A	24-04-1998 28-07-1999 09-04-1998
WO 9858598	A	30-12-1998	DE 19826675 A	04-03-1999
US 4428375	A	31-01-1984	NONE	